Immune checkpoint therapy in locally advanced, persistent, recurrent, and metastatic cervical cancer: A systematic review and Bayesian network meta‐analysis
Pembrolizumab ranked highest in OS and PFS among patients with locally advanced or advanced cervical cancer. These findings support its preferential use over other ICIs. However, direct head-to-head trials are needed to validate these results and inform optimal ICI selection.
Authors
- Mauricio Torres‐Martinez (ORCID: https://orcid.org/0000-0002-7287-0684)
- David E. Hinojosa-González (ORCID: https://orcid.org/0000-0002-0233-0607)
- Jaime A. Escarcega‐Bordagaray (ORCID: https://orcid.org/0009-0003-5577-7706)
- Fernando Martínez Heredia (ORCID: https://orcid.org/0000-0003-4716-4216)
- Regina M. Murillo‐Torres (ORCID: https://orcid.org/0009-0001-6245-7474)
Institutions
- Johns Hopkins University (US)
- University of Concepción (CL)
- Baylor College of Medicine (US)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- International Journal of Gynecology & Obstetrics
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1002/ijgo.70648
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00